Lupus Therapeutics

The Lupus Research Alliance established Lupus Therapeutics in 2017 to support the clinical research of potential new treatments for lupus. With this addition, the Lupus Research Alliance is the only organization focused on the complete spectrum of lupus research from accelerating basic discoveries in the lab through clinical trials testing new therapies.

Many of the basic research breakthroughs supported by the Lupus Research Alliance have helped unravel the complexities of lupus and enabled the development of potential treatments and diagnostics now in clinical studies. Lupus Therapeutics is actively supporting several clinical studies for potential new therapies through its Lupus Clinical Investigators Network (LuCIN). Lupus Therapeutics created and oversees LuCIN, a North America-based lupus clinical trials network of 57 top academic research medical centers

Lupus Therapeutics also offers its expertise combined with that of the Lupus Research Alliance to support academic, non-profit and biotech and pharmaceutical organizations as they plan, initiate and manage clinical research.

In addition, Lupus Therapeutics is piloting the first peer-to-peer clinical trials education program, Patient Advocates for Lupus Studies or PALS. Created by Lupus Therapeutics and the Lupus Research Alliance, PALS aims to improve clinical research awareness, knowledge, and enrollment, with a specific focus on making sure diverse populations at greatest risk for lupus are well-represented in studies.

If you are interested in participating in clinical research please speak with your physician and learn more about trials that might be right for you at Lupus Research Alliance’s dedicated clinical research website, .

To learn more about how Lupus Therapeutics can support your organization’s clinical research efforts, visit

Watch this video to learn more about Lupus Therapeutics and
find out why it will bring us better treatments for lupus faster.

Lupus Therapeutics News

Two Lupus Therapeutics Studies...

November 12, 2019 Two positive clinical studies presented at the 2019 ACR/ARP Annual Meeting were conducted through the Lupus Clinical Investigators Network...

Read More

10 Lupus Therapeutics Studies...

  TAK-079 A Study to Evaluate the Safety of TAK-079 PAISLEY-SLE A Phase II study to evaluate a novel, oral therapy in...

Read More

Welcoming Daniel J. Wallace,...

The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel J. Wallace, MD joins as a new member...

Read More

Contact Us

Lupus Therapeutics mission is to accelerate drug discovery and diagnostic innovation for all patients living with lupus. If you would like to learn more please contact us:

Learn more about ongoing clinical studies being conducted within LuCIN